Mark Purcell
Stock Analyst at Morgan Stanley
(1.39)
# 3,578
Out of 5,090 analysts
6
Total ratings
66.67%
Success rate
-4.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $49.53 | +17.10% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $132.16 | -13.74% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $48.41 | -9.11% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $90.18 | -5.74% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $47.86 | +150.73% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $49.53
Upside: +17.10%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $132.16
Upside: -13.74%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $48.41
Upside: -9.11%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $90.18
Upside: -5.74%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $47.86
Upside: +150.73%